Multiple sclerosis (MS) in children and adolescents accounts for 3—10% of the whole MS population, and is characterized by a relapsing course in almost all cases. The frequency of relapses is higher than in adult onset MS, at least in the first years of evolution. The objective of treatment is to speed the recovery after a relapse, to prevent the occurrence of relapses, and to prevent disease progression and neurodegeneration. The use of drugs for MS in children and adolescents has not been studied in clinical trials, so their use is mainly based on results from trials in adults and from observational studies. There is a consensus to treat acute relapses with intravenous high-dose corticosteroids. The possibility of preventing relapses and disease progression is based on the use of immunomodulatory agents. Interferon-beta (IFNB) and glatiramer acetate (GA) have been demonstrated to be safe and well tolerated in pediatric MS patients, and also to reduce relapse rate and disease progression. Cyclophosphamide and natalizumab could be offered as second-line treatment in patients with a poor response to IFNB or GA. New oral and injectable drugs will be available in the near future: if safe and well tolerated in the long-term follow up of adults with MS, they could be tested in the pediatric MS population.
Amato, M., Goretti, B., Ghezzi, A., Lori, S., Zipoli, V., Portaccio, E. et al. (2008) Cognitive and psychosocial features of childhood and juvenile MS. Neurology70: 1891-1897.
2.
Appleton, R.E. and Boggild, M.(2009) Natalizumab in paediatric multiple sclerosis and service implication . Dev Med Child Neurol51: 758-759.
3.
Banwell, B. ( 2005) Treatment of children and adolescents with multiple sclerosis . Expert Rev Neurotherapeutics5: 391-401.
4.
Banwell, B.L. and Anderson, P.E. ( 2005) The cognitive burden of multiple sclerosis in children . Neurology64: 891-894.
5.
Banwell, B., Ghezzi, A., Bar-Or, A., Mikaeloff, Y. and Tardieu, M. ( 2007) Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol6: 887-902.
6.
Banwell, B., Reder, A.T., Krupp, L., Tenembaum, S., Eraksoy, M., Alexey, B. et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology66: 472-476.
7.
Barnes, D., Hughes, R.A., Morris, R.W., Wade-Jones, O., Brown, P., Britton, T. et al. (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet349: 902-906.
8.
Bar-Or, A., Calabresi, P.A., Arnold, D., Markowitz, C., Shafer, S., Kasper, L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol63: 395-400.
9.
Bielekova, B., Howard, T., Packer, A.N., Richert, N., Blevins, G., Ohayon, J. et al. (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis . Arch Neurol66: 483-489.
10.
Boiko, A., Vorobeychik, G., Paty, D., Devonshire, V., Sadovnick, D. and the UBC MS Clinic Neurologists. (2002) Early onset multiple sclerosis: a longitudinal study. Neurology59: 1006-1010.
11.
Boriell, G., Prosperino, L., Lucchetti, A. and Pozzilli, C.(2009) Natalizumab treatment in pediatric multiple sclerosis: a case report . Eur J Paediatr Neurol13: 67-71.
12.
Capobianco, M., Rizzo, A., Malucchi, S., Sperli, F., Di Sapio, A., Oggero, A. et al. (2008) Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurol Sci29: S227-S229.
13.
Carson, K.R., Focosi, D., Major, E.O., Petrini, M., Richey, E.A., West, D.P. et al. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol10: 816-824.
14.
Chabas, D., Castello-Trivino, T., Mowry, E.M., Strober, J.B., Glenn, O.A. and Waubant, E. ( 2008) Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology71: 1090-1093.
15.
Cohen, J., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med362: 402-415.
16.
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O. et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357: 1576-1582.
17.
Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A. et al. (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Neurol374: 1503-1511.
18.
Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A. et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre randomised double-blind placebo-controlled phase IIb study. Lancet371: 2085-2092.
19.
Compston, A. and Coles, A. ( 2002) Multiple sclerosis. Lancet359: 1221-1231.
20.
Ellis, R. and Boggild, M.(2009) Therapy related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?Mult Scler15: 505-508.
21.
Elovaara, I., Apostolski, S., van Doorn, P., Apostolski, S., van Dororn, P., Gilhus, N.E. et al. (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological disorders. Eur J Neurol15: 893-908.
22.
Farrell, R., Kapoor, R., Leary, S., Rudge, P., Thompson, A. and Miller, D. ( 2008) Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta . Mult Scler14: 212-218.
23.
Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., De Stefano, N., Smith, S. et al. (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet364: 1489-1496.
24.
Filippini, G., Munari, L., Incorvaia, B., Ebers, G.C., Polman, C., D’Amico, R. et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet361: 545-552.
25.
Fisher, J.S., Priore, R.L., Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M. et al. (2000) Neuropsychological effects of interferon-beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol48: 885-892.
26.
Freedman, M.S., Patry, D.G., Grand’Maison, F., Myles, M.L., Paty, D.W., Selchen, D.H. et al. (2004) Treatment optimization in multiple sclerosis . Can J Neurol Sci31: 157-168.
27.
Gasperini, C. and Ruggieri, S.(2009) New oral drugs for multiple sclerosis. Neurol Sci (Suppl2): S179-S183.
28.
Ghezzi, A. ( 2005) Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurotherapeutics5: 403-411.
29.
Ghezzi, A., Amato, M.P., Annovazzi, P., Capobianco, M., Gallo, P., La Mantia, L. et al. (2009a) Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience . Neurol Sci30: 193-199.
30.
Ghezzi, A., Amato, M.P., Capobianco, M., Gallo, P., Marrosu, G., Martinelli, V. et al. (2005) Disease modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult Scler11: 420-424.
31.
Ghezzi, A., Banwell, B., Boyko, A., Amato MP, Anlar B., Blinkenberg M. et al. (2010) The management of MS in children: A European view, Mult. Scler. in press.
32.
Ghezzi, A., Pozzilli, C., Brescia-Morra, V., Bortolon, F., Capra, R., Grimaldi, L. et al. (2009b) Safety and effectiveness of natalizumab in paediatric multiple sclerosis: results of 17 patients. Mult Scler15(Suppl 2): 774.
33.
Ghezzi, A., Pozzilli, C., Liguori, M., Marrosu, M.G., Dilani, N., Milanese, C. et al. (2002) Prospective study of multiple sclerosis with early onset. Mult Scler8: 115-118.
34.
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Soelberg Sørensen, P. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med362: 416-426.
35.
Goodin, D.S., Frohman, E.M., Garmany, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology58: 169-178.
36.
Gorman, M.P., Healy, B.C., Polgar-Turcsanyi, M. and Chitnis, T.(2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol66: 54-59.
37.
Gusev, E., Boiko, A., Bikova, O., Maslova, O., Guseva, M., Boiko, S. et al. (2002) The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg104: 203-207.
38.
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C.H. et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study . Lancet Neurol8: 254-260.
39.
Hawker, K., O’Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol66: 460-471.
40.
Huppke, P., Stark, W., Zurcher, C., Huppke, B., Brück, W. and Gärtner, J. ( 2008) Natalizumab use in pediatric multiple sclerosis. Arch Neurol65: 1655-1658.
41.
Hyams, J.S., Wilson, D.C., Thomas, A. et al. (2007) Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr44: 185-191.
42.
Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med343: 898-904.
43.
Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) Intramuscular interferon beta 1-a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol39: 285-294.
44.
Johnson, K.P., Brooks, B.R., Cohen, J.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology45: 1268-1276.
45.
Kappos, L., Bates, D., Hartung, H.P., Havrdova, E., Miller, D., Polman, C.H. et al. (2007a) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol6: 431-441.
46.
Kappos, L., Freedman, M.S., Polman, C., Edan, G., Hartung, H.P., Miller, D.H. et al. (2007b) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis. Lancet Neurol370: 389-397.
47.
Kappos, L., Freedman, M., Polman, C.H., Edan, G., Hartung, H.P., Miller, D.H. et al. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol11: 987-997.
48.
Kappos, L., Gold, R., Miller, D.H., Macmanus, D.G., Havrdova, E., Limmroth, V. et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre randomised double-blind placebo-controlled phase Iib study. Lancet372: 1463-1472.
49.
Kappos, L., Polman, C., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67: 1242-1249.
50.
Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med362: 387-401.
51.
Karenfort, M., Kieseier, B.C., Tibussek, D., Assmann, B., Schaper, J. and Mayatepek, E.(2009) Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol51: 159-161.
52.
Kornek, B., Bernert, G., Balassy, C., Geldner, J., Prayer, D. and Feucht, M. ( 2003) Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics34: 120-126.
53.
Lehmann, H.C., Hartung, H.P., Hetzel, G.R., Stüve, O. and Kieseier, B.C. ( 2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders . Arch Neurol63: 930-935.
54.
MacAllister, W.S., Belman, A.L., Milazzo, M., Weisbrot, D.M., Christodoulou, C., Scherl, W.F. et al. (2005) Cognitive functioning in children and adolescents with multiple sclerosis. Neurology64: 1422-1425.
Malucchi, S., Gilli, F., Caldano, M., Marnetto, F., Valentino, P., Granieri, L. et al. (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology70: 1119-1127.
57.
Martinelli, V., Capra, R. and Cocco, E.(2009) High incidence of acute leucemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study. Mult Scler (Suppl2): S167-S170.
58.
Mikaeloff, Y., Caridde, G., Tardieu, M. and Suissa, S. ( 2008) Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative study. Eur J Paediatr Neurol12: 205-209.
59.
Mikaeloff, Y., Moreau, T., Debouverie, M., Pelletier, J., Lebrun, C., Gout, O. et al. (2001) Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr139: 443-446.
60.
Morrow, S.A., Stoian, C.A., Dmitrovic, J., Chan, S.C. and Metz, L.M. ( 2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology63: 1079-1080.
61.
O’Connor, P.W., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C., Paty, D.W. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66: 894-900.
62.
Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology49: 1404-1413.
63.
Pakdaman, H., Fallah, A., Sahraian, M.A., Pakdaman, R. and Meysamie, A. ( 2006) Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics37: 257-260.
64.
Patti, F., Amato, M.P., Bastianello, S., Caniatti, L., Di Monte, E., Ferrazza, P. et al. (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler16: 68-77.
65.
Pohl, D., Rostasy, K., Gartner, J. and Hanefeld, F. ( 2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology65: 888-890.
66.
Pohl, D., Rostasy, K., Reiber, H. and Hanefeld, F. ( 2004) CSF characteristics in early-onset multiple sclerosis . Neurology63: 1966-1967.
67.
Polman, C.H., O’Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med354: 899-910.
68.
Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2006) Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler12: 281-286.
69.
PRISM Study Group (1998) Randomized double-blind placebo controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis. Lancet352: 1498-1504.
70.
Renoux, C., Vukusic, S., Mikaeloff, Y., Mikaeloff, Y., Edan, G., Clanet, M. et al. (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med365: 2603-2613.
71.
Rio, J., Castello, J., Rovira, A., Tintoré, M., Sastre-Garriga, J., Horga, A. et al. (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler15: 848-853.
72.
Rio, J., Nos, C., Tintorè, M., Téllez, N., Galán, I., Pelayo, R. et al. (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol59: 344-352.
73.
Rio, J., Rovira, A., Tintoré, M., Huerga, E., Nos, C., Tellez, N. et al. (2008) Relationship between MRI lesion activity and response to IFNβ in relapsing remitting multiple sclerosis patients. Mult Scler14: 479-484.
74.
Rudick, R., Lee, J., Simon, J., Ransohoff, R.M. and Fisher, E. ( 2004) Defining interferonβ response status in multiple sclerosis . Ann Neurol56: 548-555.
75.
Sørensen, P.S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K.M., Palace, J. et al. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol12: 817-827.
76.
Sørensen, P.S., Tscherning, T., Mathiesen, H.K., Langkilde, A.R., Ross, C., Ravnborg, M. et al. (2006) Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology67: 1681-1683.
77.
Soriani, M.P., Bonzano, L., Roccatagliata, L., Cutter, G.R., Mancardi, G.L., Bruzzi, P. et al. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis. A meta-analytic approach. Ann Neurol65: 268-275.
78.
Takahashi, I., Sawaishi, Y., Takeda, O., Enoki, M. and Takada, G. ( 1997) Childhood multiple sclerosis treated with plasmapheresis . Pediatr Neurol17: 83-87.
79.
Tenembaum, S.N. and Segura, M.J. ( 2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology67: 511-513.
80.
The CAMMS223 Trial Investigators (2008) Alentuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med359: 1786-1801.
81.
The IFNB Multiple Sclerosis Study Group (1993 ) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology43: 655-661.
82.
The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology53: 1277-1285.
83.
Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C. et al. (2006) Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J Neurol253: 287-293.
84.
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zipoli, V., Zimatore, G.B. et al. (2007) New natural history of interferon-beta treated relapsing multiple sclerosis. Ann Neurol61: 300-306.
85.
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zimatore, G.B., Tortorella, C. et al. (2009) Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol66: 513-520.
86.
Waubant, E., Chabas, D., Okuda, D., Glenn, O., Mowry, E., Henry, R.G. et al. (2009) Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol66: 967-971.
87.
Waubant, E., Hietpas, J., Stewart, T., Dyme, Z., Herbert, J., Lacy, J. et al. (2001) Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics32: 211-213.
88.
Weinshenker, B.G., O’Brien, P.C., Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F., Dodick, D.W. et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol46: 878-886.
89.
Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med354: 924-933.
90.
Zivadinov, R., Rudick, R.A., De Masi., Nasuelli, D., Ukmar, M., Pozzi-Mucelli, R.S. et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology57: 1239-1247.
